To test this hypothesis, we focused on aliskiren affecting the in vitro function and in vivo reendothelialization capability of early EPCs from patients with hypertension, evaluated the regulatory effects of aliskiren on the Tie2/Pl3k/Akt/eNOS signalling pathway in EPCs, and studied the role of this signalling pathway in the aliskiren-mediated regulation of EPC function in vitro and reendothelialization capability in vivo in mice. The gene discussed is TEK; the disease is hypertensive disorder.